Alps Advisors Inc. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 291,765 shares of the biopharmaceutical company’s stock after selling 11,592 shares during the quarter. Alps Advisors Inc. owned 0.20% of Halozyme Therapeutics worth $4,525,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of HALO. FMR LLC grew its position in Halozyme Therapeutics by 5.0% in the first quarter. FMR LLC now owns 2,685,575 shares of the biopharmaceutical company’s stock valued at $43,238,000 after acquiring an additional 127,379 shares in the last quarter. First Trust Advisors LP grew its position in Halozyme Therapeutics by 18.6% in the first quarter. First Trust Advisors LP now owns 97,659 shares of the biopharmaceutical company’s stock valued at $1,572,000 after acquiring an additional 15,320 shares in the last quarter. Arbor Investment Advisors LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $308,000. CWM Advisors LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $175,000. Finally, Taylor Wealth Management Partners grew its position in shares of Halozyme Therapeutics by 0.4% during the second quarter. Taylor Wealth Management Partners now owns 205,084 shares of the biopharmaceutical company’s stock worth $3,523,000 after buying an additional 735 shares in the last quarter. 82.50% of the stock is owned by institutional investors.
A number of analysts have recently weighed in on the stock. ValuEngine downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price target for the company in a research report on Thursday. BidaskClub downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Barclays raised shares of Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and decreased their price target for the stock from $17.00 to $16.00 in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $20.50.
HALO stock opened at $16.87 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $13.24 and a twelve month high of $17.79. The company has a current ratio of 2.89, a quick ratio of 2.57 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $2.50 billion, a P/E ratio of -30.13 and a beta of 1.78. The firm has a 50 day simple moving average of $15.70 and a 200-day simple moving average of $16.13.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The business had revenue of $39.10 million during the quarter, compared to the consensus estimate of $42.94 million. Halozyme Therapeutics had a negative net margin of 23.53% and a negative return on equity of 16.97%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.16) earnings per share. On average, research analysts predict that Halozyme Therapeutics, Inc. will post -0.32 EPS for the current year.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
See Also: What is a balanced fund?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.